Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 4Phase 1 4Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × eltrombopag × Clear all
NCT01286675 2019-03-01

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Completed
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡